Michael Schmitz
Stock Analyst at Guggenheim
(1.29)
# 3,271
Out of 4,789 analysts
15
Total ratings
42.86%
Success rate
-3.92%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Maintains: Buy | $72 → $82 | $33.77 | +142.86% | 2 | Oct 28, 2024 | |
| MRUS Merus | Maintains: Buy | $93 → $111 | $40.01 | +177.43% | 2 | Oct 1, 2024 | |
| BPMC Blueprint Medicines | Maintains: Buy | $130 → $138 | $85.56 | +61.29% | 8 | Aug 2, 2024 | |
| ARVN Arvinas | Upgrades: Buy | $40 | $7.01 | +470.61% | 1 | Nov 20, 2023 | |
| FATE Fate Therapeutics | Downgrades: Neutral | n/a | $0.76 | - | 1 | Jan 3, 2023 | |
| NOVA Sunnova Energy International | Initiates: Buy | $15 | $0.35 | +4,184.49% | 1 | Jan 6, 2020 |
Revolution Medicines
Oct 28, 2024
Maintains: Buy
Price Target: $72 → $82
Current: $33.77
Upside: +142.86%
Merus
Oct 1, 2024
Maintains: Buy
Price Target: $93 → $111
Current: $40.01
Upside: +177.43%
Blueprint Medicines
Aug 2, 2024
Maintains: Buy
Price Target: $130 → $138
Current: $85.56
Upside: +61.29%
Arvinas
Nov 20, 2023
Upgrades: Buy
Price Target: $40
Current: $7.01
Upside: +470.61%
Fate Therapeutics
Jan 3, 2023
Downgrades: Neutral
Price Target: n/a
Current: $0.76
Upside: -
Sunnova Energy International
Jan 6, 2020
Initiates: Buy
Price Target: $15
Current: $0.35
Upside: +4,184.49%